News

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that the European Commission (EC) approved VYVGART…
Read More...

Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, announced a global strategic…
Read More...

Archeus Technologies announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting…
Read More...

Health Canada has approved Novartis' KISQALI (ribociclib tablets) in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor-positive (HR+),…
Read More...

Advarra announced the launch of the Council for Responsible Use of AI in Clinical Trials. The Council, which includes leaders from across the life sciences industry, will focus on…
Read More...

RyboDyn, Inc., a biotechnology company pioneering first-in-class immunotherapies targeting the dark proteome, announced its selection to join Lilly Gateway Labs (LGL) in San Diego, an…
Read More...

Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo (lenacapavir) as a pre-exposure prophylaxis (PrEP) to prevent sexually acquired HIV-1.…
Read More...

Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new therapeutics that target shared underlying…
Read More...

Ferrer has announced that its investigational therapy FNP-223, developed to treat progressive supranuclear palsy (PSP), has received Fast Track designation from the U.S. Food and Drug…
Read More...

Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand approval of…
Read More...

Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, launches from stealth having raised a total of $140 million (£107…
Read More...

Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its investigational drug DYNE-101 for the treatment of…
Read More...

BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that the U.S. Food and Drug Administration (FDA) has…
Read More...

Eli Lilly and Company and Verve Therapeutics, Inc., a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, announced a definitive agreement for…
Read More...

Lisata Therapeutics, Inc. and GATC Health Corp. announced a strategic alliance designed to accelerate and improve the success rate of the traditional drug development process. This…
Read More...

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs Orion Corporation and Glykos Finland Oy…
Read More...

Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), announced an international collaboration with…
Read More...

Global pharma major Lupin Limited (Lupin) announced that it has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP), for the commercialization of Tiotropium…
Read More...

Celltrion, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA (ustekinumab-stba), a biosimilar to STELARA (ustekinumab), in a…
Read More...

NextCure, Inc. has announced a strategic collaboration with Simcere Zaiming, an oncology-focused subsidiary of Simcere Pharmaceutical Group Ltd. The partnership centers on the…
Read More...